A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

NCT06509971 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Platinum-resistant Recurrent Ovarian Cancer

Interventions

DRUG: QL1706

Sponsor

West China Second University Hospital